Alpha Tau Medical Ltd.

NasdaqCM DRTS

Alpha Tau Medical Ltd. Cash and Short-Term Investments for the year ending December 31, 2023: USD 81.79 M

Alpha Tau Medical Ltd. Cash and Short-Term Investments is USD 81.79 M for the year ending December 31, 2023, a -21.76% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Alpha Tau Medical Ltd. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 104.53 M.
Alpha Tau Medical Ltd. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 46.02 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: DRTS

Alpha Tau Medical Ltd.

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street
Employees	121
Sector	Health Care
Industries Clinical Trials Biotechnology Pharmaceuticals

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends

Past 5 years